Up to 1 in 6 men with prostate cancer have a hereditary form of cancer1

These patients have inherited a cancer-causing mutation (BRCA) in every cell of their body and only germline testing (blood or saliva) can determine those patients that have hereditary disease.

It is very important to identify the BRCA positive patients for several reasons

They are 6 times more likely to die of prostate cancer within 5 years2

They are 4 times more likely to develop prostate cancer metastasis within 5 years2

These patients are at a higher risk of developing other primary cancers3

They live around 7 years less on average2

The siblings and children of these patients have a 50% chance of having the same genetic mutation

Myriad MyRisk Hereditary Cancer Test is a scientific advancement revolutionizing hereditary cancer testing

Prostate cancer patients with BRCA mutations are associated with poor survival outcomes and should be considered for tailored clinical management.2

  • Poly (ADP-ribose) polymerase (PARP) inhibitors have specific activity in BRCA-associated cancers including prostate cancer2
  • Mutation carriers may also respond better to platinum-based chemotherapy2
  • Screening for secondary cancers should be included in management

ORDER TEST KIT HOW DOES MYRISK WORK?

Hear about Dr. Timothy Goodson’s experience with myRisk testing

What Patients to Test

To determine what patients are recommended by NCCN for hereditary cancer testing and to see what patients are covered by Medicare, download the sheet below.

Download File

For more information on how to implement hereditary cancer testing in your practice or to connect with your field representative:

Email: MyriadUrology@myriad.com

Field Representative 800-469-7423

Clinical Questions UrologyMedical@myriad.com

What other tests does Myriad Urology offer?

Makes Treatment Decisions Easier

Prolaris adds clinically proven information to traditional diagnostic tools and spells out how quickly a patient’s prostate cancer will progress. Put simply, a Prolaris test helps you present truly informed treatment options to your patient – providing you both confidence in your decisions.

LEARN MORE ABOUT PROLARIS

References

  1. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. Nicolosi et al. JAMA Oncol 2019.
  2. Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. Castro et al. J Clin Oncol 31 (2013).
  3. For the most up-to-date general population and syndrome-associated cancer risks, please refer to the Gene Table at https:www.MyriadPro.com/myRisk.